Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NEU-411

Small molecule · Inhibitor of leucine-rich repeat kinase 2 (LRRK2) · developed by Neuron23

Phase 2 Most advanced trial
1 Registered trials

What is NEU-411?

NEU-411 is an orally bioavailable, brain-penetrant small molecule that selectively inhibits LRRK2 kinase activity. It is being studied in Parkinson disease, including early Parkinson disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
leucine-rich repeat kinase 2 (LRRK2)
Mechanism
Inhibitor of leucine-rich repeat kinase 2 (LRRK2)
Therapy area
Neurology
Developer
Neuron23 Inc.
In trials of
QGEN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06680830 Phase 2 Parkinson Disease Recruiting QGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Early Parkinson Disease (Early PD)Idiopathic Parkinson DiseaseParkinsonParkinson DiseaseParkinson Disease, Idiopathic

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.